Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

Robert J Petrella1 Department of Family Medicine and Cardiology, Lawson Health Research Institute, University of Western Ontario, ON, CanadaCorrespondence[email protected]

Guy Tremblay2 Centre hospitalier universitaire de Québec, Hôpital du Saint-Sacrement, Sainte-Foy, Québec, QC, Canada

Guy De Backer3 Department of Public Health, Ghent University, Ghent, Belgium

Dawn P Gill4 Aging, Rehabilitation and Geriatric Care Research Centre, Lawson Health Research Institute, London, ON, Canada;5 School of Health Studies, Western University, London, ON, Canada;6 Department of Epidemiology, University of Washington, Seattle, WA, USA

Pages 63-74 | Published online: 29 Jan 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

RobitailleCDaiSWatersCDiagnosed hypertension in Canada: incidence, prevalence and associated mortalityCMAJ20121841E49E5622105752
PubMed Web of Science ®Google Scholar
DaskalopoulouSSKhanNAQuinnRRCanadian Hypertension Education ProgramThe 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapyCan J Cardiol20122827028722595447
PubMed Web of Science ®Google Scholar
PadwalRSHemmelgarnBRKhanNACanadian Hypertension Education ProgramThe 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of riskCan J Cardiol20092527928619417858
PubMed Web of Science ®Google Scholar
GroverSAHemmelgarnBJosephLMilotATremblayGThe role of global risk assessment in hypertension therapyCan J Cardiol20062260661316755316
PubMed Web of Science ®Google Scholar
WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWBPrediction of coronary heart disease using risk factor categoriesCirculation199897183718479603539
PubMed Web of Science ®Google Scholar
De BackerGPetrellaRJGoudevARRadaidehGARynkiewiczAPathakADesign and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertensionFundam Clin Pharmacol20132721021522049922
PubMed Web of Science ®Google Scholar
De BackerGPetrellaRJGoudevARRadaidehGARynkiewiczAPathakAEffect of antihypertensive therapy on SCORE-estimated total cardiovascular risk: results from an open-label, multinational investigation -the POWER surveyInt J Hypertens EpubJuly252013
Google Scholar
Health Canada [database on Internet] Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=67885&lang=engAccessed December 11, 2013
Google Scholar
LiddyCHoggWRussellGImproved delivery of cardiovascular care (IDOCC) through outreach facilitation: study protocol and implementation details of a cluster randomized controlled trial in primary careImplement Sci2011611021952084
PubMed Web of Science ®Google Scholar
CampbellNYoungERDrouinDA framework for discussion on how to improve prevention, management, and control of hypertension in CanadaCan J Cardiol20122826226922284588
PubMed Web of Science ®Google Scholar
CarterMKarwalajtysTChambersLCHAP Working GroupImplementing a standardized community-based cardiovascular risk assessment program in 20 Ontario communitiesHealth Promot Int20092432533319819896
PubMed Web of Science ®Google Scholar
TattersallMCKarmaliKNGangnonREKeevilJGThe population effects of the global cardiovascular risk model in United States adults: findings from the National Health and Nutrition Surveys, 2005–2006J Clin Lipidol2011516617221600521
PubMed Web of Science ®Google Scholar
LuGCChengJWZhuKMMaXJShenFMSuDFA systematic review of angiotensin receptor blockers in preventing strokeStroke2009403876387819892999
PubMed Web of Science ®Google Scholar
DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
PubMed Web of Science ®Google Scholar
LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens20032187588612714861
PubMed Web of Science ®Google Scholar
SchraderJLüdersSKulschewskiAMorbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)Stroke2005361218122615879332
PubMed Web of Science ®Google Scholar
SteinerSHelisEChenLA cross-national comparative study of blood pressure levels and hypertension prevalence in Canada and HungaryJ Hypertens2012302105211123027179
PubMed Web of Science ®Google Scholar
ThanassoulisGLyassABenjaminEJRelations of exercise blood pressure response to cardiovascular risk factors and vascular function in the Framingham Heart StudyCirculation20121252836284322572915
PubMed Web of Science ®Google Scholar
AndreadisEASfakianakisMETsourousGIDifferential impact of angiotensin receptor blockers and calcium channel blockers on arterial stiffnessInt Angiol20102926627220502415
PubMed Web of Science ®Google Scholar
InabaSIwaiMFurunoMTemporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodelingAm J Hypertens20112455055621293390
PubMed Web of Science ®Google Scholar
OnoYNakayaYBandoSSoekiTItoSSataMTelmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular functionInt Heart J200950738319246848
PubMed Web of Science ®Google Scholar
IinoKWatanabeHIinoTCandesartan improves impaired endothelial function in the human coronary arteryCoron Artery Dis20122327828322343799
PubMed Web of Science ®Google Scholar
SozenABKayacanMSTanselTDrugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patientsJ Int Med Res200937996100219761681
PubMed Web of Science ®Google Scholar
LiuRSoLMohanSKhanNKingKQuanHCardiovascular risk factors in ethnic populations within Canada: results from national cross-sectional surveysOpen Med20104e143e15321687334
PubMedGoogle Scholar
ChiuMAustinPCManuelDGTuJVCardiovascular risk factor profiles of recent immigrants vs long-term residents of Ontario: a multi-ethnic studyCan J Cardiol201228202621827964
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date